Hybribio is a leading provider for in vitro diagnostic assays in Greater China with fully integrated operation chain from R&D, manufacturing, sales & marketing to after-sales technical support service. As of year 2016, over 16 million tests of our HPV Genotyping test has been performed in China. Furthermore, we are the sole company collaborating with the Ministry of Health in Chinese Government to establish the first HPV database system in China. Based on technological platforms such as our proprietary flow-through hybridization technology, real-time PCR technology, and high throughput sequencing, our two major R&D lines – infectious pathogens detection and genetic disease detection – include human papillomavirus (HPV), thalassemia, G6PD, hearing loss susceptibility, phenylketonuria (PKU), and early cancer detection etc. Our products have been widely used in the fields of clinical detection, large scale screening, and prenatal and neonatal management.
Three As – authentic, accurate, and affordable – have been the core values of our product, which have made us one of the biggest molecular diagnostic companies in China. Currently Hybribio employs over 800 staffs with 2 GMP plants and 25 regional offices. We provide product and services to over 1200 hospitals and medical institutes in China. Over 180 scientists and technical personnel are stationed in China and Hong Kong, providing on-site technical training and after-sales technical service support.
Working along with partners from different countries, our sales and marketing teams aim for providing an effective strategic marketing plan catered for different markets. More than 25 countries in Asia Pacific, South East Asia, Middle East, Europe, Africa, and South America use our IVD products for national screening, clinical and research purposes.
To better serve our community, we are establishing a network of our own clinical lab centers covering all major cities in China. We already have operational centers in Hong Kong, Beijing, Shanghai, Guangzhou, Zhengzhou, Shenyang, and Kunming, and will have more than 20 sites before 2017.
This year we have started clinical validations of our HPV diagnostic kits both in China and in Europe. The both validations will fulfill the Chris Meijer guidelines published in 2009. In October 2016, Hybribio flow-through hybridization technology, among other 20 leading enterprises including Sinopec and Huawei, was awarded the 18th WIPO-SIPO joint China Patent Gold Medal, the only molecular diagnostic enterprise this year to receive this award.
One of our core corporate goals is to foster a long-lasting cooperative relationship with our partners. It is our mission to provide the local community with quality service and comprehensive testing. By incorporating your strength and service to our list of collaborations, we hope it will bring us one step closer to our goal.